Skip to main content
. 2016 Jan 4;11(1):e0145195. doi: 10.1371/journal.pone.0145195

Fig 1. Liposomal C8 ceramide inhibits HCC cell proliferation and survival.

Fig 1

HepG2 (A-D), SMMC-7721 (E and F) and Huh-7 (E and F) human HCC cells, as well as HL7702 human hepatocytes (E and F) were either left untreated (“C”, same for all figures), or treated with applied concentrations of liposomal C8 ceramide (“Lipo C8”, same for all figures) or free C8 ceramide (For “A”) for indicated time, cell proliferation was tested by MTT assay (A, B and E) or clonogenicity assay (C, for HepG2 cells), and cell death was tested by trypan blue staining assay (D and F). Data represent the means of three independent experiments ± standard deviations (SD). The asterisks (*) indicate statistically significant differences compared to “C” group.